newsfilter
← Latest News
GlobeNewswire·

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

– Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., March 12, 2026 (GLOBE